SWOT Analysis for Lyell Immunopharma Inc

Companies with 10% increase in share price over three months, with rising net profit growth
Relative Outperformance versus Industry over 1 Month
Relative Outperformance versus Industry over the Quarter (3 Months)
PEG lower than Industry PEG
High Momentum Scores (Technical Scores greater than 50)
Relative Outperformance versus Industry over 1 Week
Relative Outperformance versus Industry over 1 Month
Companies with Low Debt
Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
Stock gained more than 20% in one month
Stock with Low PE (PE < = 10)
RSI indicating price strength
Stocks Outperforming their Industry Price Change in the Quarter

Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Inefficient use of shareholder funds - ROE declining in the last 2 years
Inefficient use of assets to generate profits - ROA declining in the last 2 years
Highest fall from 52 Week High
Top Losers
Low Piotroski Score : Companies with weak financials
Declining Net Cash Flow : Companies not able to generate net cash
Annual net profit declining for last 2 years
Book Value Per Share deteriorating for last 2 years
Declining Revenue every quarter for the past 2 quarters
Top Losers